CEPI’s 2022-2026 Strategy (CEPI 2.0) and the related programme document articulates the strategic objectives of “Prepare, Transform and Connect” and outlines CEPIs ambitious programme that aim to substantially reduce global epidemic and pandemic threats. The ecosystem for pandemic preparedness and response is rapidly evolving, and subject to high-level political discussions on global, regional and national level. The COVID-19 pandemic has exposed the critical need for fully funded, prepositioned and coordinated financing mechanisms to ensure appropriate preparedness for and response to future potential pandemic threats. CEPI aims to help drive the political commitment to secure sustainable and sufficient end-to-end funding for R&D both in interpandemic periods and during outbreak response, including surge funding for R&D, manufacturing ‘at-risk’ and advanced purchase commitments (APAs), to incentivize R&D and manufacturing, and facilitate equitable access. A key initial focus of the Policy manager will be to lead on CEPIs positioning towards ongoing discussions at both the global level (G20, G7, WB), regional (EC, AU) and national levels about the future financing mechanisms and their interrelations discussions on financing and developing a corresponding financing strategy in close cross-cutting collaboration, in particular with the Strategy team and the Resource Mobilization/Investor Relations team.
- Support CEPIs external policy work in a flexible manner as required given the rapidly evolving ecosystem
- Monitor, systematically collect and analyse information about identified external policy drivers with a view to developing policy advice for CEPI.
- Develop and continuously evolve CEPI positions in key pandemic preparedness and response ecosystem areas, including R&D, financing, low and middle income country challenges and equitable access.
- Project manage cross-cutting teams in the development of evidence-based policy positions that CEPI may advocate for externally
- Serve as CEPI as a subject matter expert on health policy and advocacy.
- Carry relationship management role versus key identified strategic partnerships, securing cross-cutting alignment and approach
- The ability to offer policy advice on financing mechanisms incl. ODA (Official Development Assistance), Innovative Financial Instruments and Development Finance in the context of the global health ecosystem is an advantage although not an essential requirement for this role.
- Other responsibilities that the candidate may be called on to undertake in accordance with the role of Policy Manager
- Self-starter with strong planning and project management skills, and with a flexible, positive, pro-active attitude.
- Strong written and oral communication skills, with demonstrated ability to deliver high quality work within tight deadlines
- A track record of resilience, sound judgment and decisiveness in pressured circumstances.
- Ability to analyse and offer policy recommendations on complex, multi-facetted issues in the global health environment.
- Strong interpersonal skills and ability to work collaboratively with colleagues and partners from a wide range of disciplines, backgrounds, and cultures. Experience working in a matrix organisational or team structure is a strong plus
- Demonstrated experience working with financial mechanisms, incl. innovative financial instruments. is advantageous
- Bachelor’s or master’s degree in a relevant discipline (life sciences, public health, public policy, international affairs, economics, business administration or another relevant subject)
- Demonstrated (5 + years) of relevant professional experience (e.g. global health, strategy, biotech R&D), including experience of working with global health organisations/architecture
CEPI is an innovative partnership between public, private, philanthropic, and civil organisations, launched at Davos in 2017, to develop vaccines against future epidemics. Prior to COVID-19, CEPI’s work focused on developing vaccines against the Ebola Virus Disease, Lassa virus, Middle East Respiratory Syndrome coronavirus, Nipah virus, Rift Valley Fever virus and Chikungunya virus. It has over 20 vaccine candidates against these pathogens in development. CEPI has also invested in new platform technologies for rapid vaccine development against unknown pathogens (Disease X).
During the COVID-19 pandemic, CEPI initiated multiple programmes to develop vaccines against SARS-CoV-2 and its variants with a focus on speed, scale, and access. These programmes leverage the rapid response platforms developed by CEPI’s partners prior to the emergence of COVID-19, as well as new collaborations. The aim is to advance clinical development of a diverse portfolio of safe and effective COVID-19 candidates and to enable fair allocation of these vaccines worldwide through COVAX.
CEPI’s 5-year plan lays out a $3.5 billion roadmap to compress vaccine development timelines to 100 days, develop a broadly protective vaccine against COVID-19 and other Betacoronaviruses, and create a “library” of vaccine candidates for use against known and unknown pathogens. The plan is available at www.endpandemics.cepi.net